EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase I)Klinische Studie (Phase II)

Combined agonism of nutrient receptors GPR40 and GPR119 with K‐757 and K‐833 results in weight loss and blood pressure reductions in obese subjects without type 2 diabetes mellitus

Michael Crutchlow, Jiajun Liu, Christopher Romero, Elaine Watkins, Harry Zhang, Anna Arreglado, Annemarie Vance, Daniel Boisvert, Giuseppe Terracina, Bryan Chan, Matt J Consolati, Gregory Poterewicz und 2 weitere

Diabetes, Obesity and Metabolism · 2025

DOI: 10.1111/dom.70120 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, 2025. Verfasst von Michael Crutchlow und 13 weiteren Autor:innen. Beteiligte Einrichtung: Kallyope, Inc., New York, New York, USA. Hauptthemen laut MEDLINE: Receptors, G-Protein-Coupled, Obesity, Weight Loss, Blood Pressure. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

K‐757 and K‐833 are novel full agonists of GPR40 and GPR119, respectively, which are nutrient receptors co‐expressed on both pancreatic beta cells and gut enteroendocrine cells that signal through complementary mechanisms. We sought to assess the effects beyond glucose control of co‐agonism with K‐757 and K‐833. Materials and Methods A Phase 1 study of the combination of K‐757 and K‐833 was conducted in overweight–obese participants to identify dose regimens causing maximal secretion of multiple gut hormones. Subsequently, a randomised, double‐blind, parallel arm and 13‐week Phase 2a study was conducted to assess the effects of K‐757 alone and in combination with K‐833, in comparison to placebo ( n = 155 [51–52/arm]).

Results

Co‐administration of K‐757 120 mg twice daily (BID) and K‐833 100 mg BID resulted in elevations of circulating glucagon‐like peptide 1 (3.44×), active glucagon‐like peptide 1 (5.06×), peptide YY (8.63×), glucagon dependent insulinotropic peptide (1.65×), cholecystokinin (3.06×) and oxyntomodulin (5.66×) relative to placebo. In Phase 2a, placebo‐adjusted weight loss with the K‐757 + K‐833 combination and K‐757 alone was −2.78% ( p < 0.001) and −1.42% ( p = 0.0756), respectively. Though blood pressure, an exploratory endpoint, was not elevated at baseline, placebo‐adjusted reductions were observed with the combination (−6.9/−5.4 mmHg) and K‐757 alone (−5.3/−3.2 mmHg). Gastrointestinal adverse events (AEs) and discontinuation due to AEs were more common in the active treatment arms. The combination and K‐757 alone were otherwise well tolerated.

Conclusions

K‐757, alone and in combination with K‐833, elicited robust elevations in circulating concentrations of multiple satiety peptides, which elicited some weight loss and blood pressure reductions that suggest potential for metabolic benefit independent of weight loss.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, G-Protein-CoupledObesityWeight LossBlood PressureHumansMaleFemaleDouble-Blind MethodMiddle AgedAdultDiabetes Mellitus, Type 2Drug Therapy, CombinationBenzofuransSulfones

Stichwörter der Autor:innen

antiobesity drugclinical trialobesity therapyphases 1 and 2 studyrandomised trialweight management

Substanzen

Receptors, G-Protein-CoupledGPR119 protein, humanFFAR1 protein, humanTAK-875BenzofuransSulfones

Autor:innen und Institutionen

  • Kallyope, Inc., New York, New York, USA.
  • Headlands Research, Brownsville, Texas, USA.
  • ProSciento, Chula Vista, California, USA.
  • BCH Research Solutions, LLC, Conshohocken, Pennsylvania, USA.

ORCID-Profile: Brett Lauring

Zitieren

APA

Crutchlow, M., Liu, J., Romero, C., Watkins, E., Zhang, H., Arreglado, A., Vance, A., Boisvert, D., Terracina, G., Chan, B., Consolati, M. J., Poterewicz, G., Talaty, J. E., & Lauring, B. (2025). Combined agonism of nutrient receptors GPR40 and GPR119 with K‐757 and K‐833 results in weight loss and blood pressure reductions in obese subjects without type 2 diabetes mellitus. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70120

Vancouver

Crutchlow M, Liu J, Romero C, Watkins E, Zhang H, Arreglado A, et al. Combined agonism of nutrient receptors GPR40 and GPR119 with K‐757 and K‐833 results in weight loss and blood pressure reductions in obese subjects without type 2 diabetes mellitus. Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.70120

BibTeX
@article{Crutchlow2025,
  author = {Crutchlow, Michael and Liu, Jiajun and Romero, Christopher and Watkins, Elaine and Zhang, Harry and Arreglado, Anna and Vance, Annemarie and Boisvert, Daniel and Terracina, Giuseppe and Chan, Bryan and Consolati, Matt J and Poterewicz, Gregory and Talaty, Jennifer E and Lauring, Brett},
  title = {Combined agonism of nutrient receptors GPR40 and GPR119 with K‐757 and K‐833 results in weight loss and blood pressure reductions in obese subjects without type 2 diabetes mellitus},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2025},
  doi = {10.1111/dom.70120}
}
Kostenlos starten →